TerminatedPhase 2NCT00002735
SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue
Studying Squamous cell carcinoma of the hypopharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Susan G. Urba, MD, MDUniversity of Michigan Rogel Cancer Center
- Intervention
- Induction chemotherapy(drug)
- Enrollment
- 68 target
- Eligibility
- 18-120 years · All sexes
- Timeline
- 1996 – 2005
Study locations (18)
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
- University of Colorado Cancer Center, Denver, Colorado, United States
- University of Kansas Medical Center, Kansas City, Kansas, United States
- MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States
- Veterans Affairs Medical Center - Ann Arbor, Ann Arbor, Michigan, United States
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
- Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
- Henry Ford Hospital, Detroit, Michigan, United States
- Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri, United States
- Veterans Affairs Medical Center - Brooklyn, Brooklyn, New York, United States
- Cleveland Clinic Cancer Center, Cleveland, Ohio, United States
- Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
- Veterans Affairs Medical Center - Oklahoma City, Oklahoma City, Oklahoma, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002735 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the hypopharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07063212A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06761937Thermoradiotherapy for Locally Advanced Head and Neck Cancer PatientsErasmus Medical Center
- RECRUITINGPHASE3NCT06706401Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaCentre Leon Berard
- RECRUITINGNCT06380686Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and OutcomeAIO-Studien-gGmbH
- RECRUITINGPHASE3NCT06525220A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.
- RECRUITINGPHASE3NCT05333523Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.Radboud University Medical Center
- RECRUITINGPHASE2NCT04858269First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsWake Forest University Health Sciences
- ACTIVE NOT RECRUITINGPHASE3NCT04590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerAstraZeneca
See all trials for Squamous cell carcinoma of the hypopharynx →